Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05214183
Other study ID # NLG-MCL8 ALTAMIRA
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 15, 2021
Est. completion date January 2027

Study information

Verified date February 2024
Source Nordic Lymphoma Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL). Acalabrutinib (ACP-196) is a next generation bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab. In this trial proposal, we will also assess the activity of this combination in comparison to a historical control of ibrutinib + rituximab, consisting of the experimental arm of ibrutinib + rituximab in the randomized ENRICH trial (EudraCT number 2015-000832-13), and data from our previous trial with R-bendamustine-lenalidomide (NLG-MCL4). The duration of treatment will be a minimum of 12 months. Patients in molecular remission in blood and bone marrow and in complete remission according to CT, will then stop acalabrutinib, but continue on rituximab for a maximum of 36 months. Patients that are minimal residual disease positive (MRD+) will be evaluated again every 6 months and continue on acalabrutinib for a maximum of 36 months. Patients without a molecular marker, that cannot be followed with MRD, will stop treatment if in CR with PET at 12 months, and be followed by PET-CT every 6 months for a maximum of 36 months. Patients who convert back to MRD positive after stopping acalabrutinib are reinstalled on acalabrutinib until progression. Patients with TP53 aberrations and/or blastoid histology, will monitor MRD but continue with treatment until progression regardless of MRD results. A planned interim analysis will be performed when 40 patients have undergone response assessment after 6 months, for futility and efficacy. If less than 16 of 40 patients obtain a CR, the trial will be stopped due to futility.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 81
Est. completion date January 2027
Est. primary completion date January 2027
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: 1. Age =60 years 2. Pathologically confirmed MCL (according to the 2016 WHO classification), with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1 3. Stage II-IV, measurable by imaging and requiring treatment in the opinion of the treating clinician 4. No previous treatment for MCL (other than localised radiotherapy or 7-day pulse of steroids for symptom control) 5. ECOG performance status 0 - 2 6. Absolute neutrophil count (ANC) > 1.0 x 109 and platelet count >100 x 109, unless related to lymphoma - in this situation, the threshold for inclusion is ANC > 0.5 x 109 and platelet count > 50 x 109 7. Creatinine clearance > 30 ml/min (Cockcroft-Gault) 8. AST and/or ALT <3xULN and/or total bilirubin <3xULN 9. Able to give voluntary written informed consent 10. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib or for 12 months after last dose of rituximab, whichever is longer Exclusion Criteria: 1. Patients considered fit enough to undergo autologous or allogeneic stem cell transplant for MCL 2. Major surgery within two weeks prior to day 1 of cycle 1 3. Patients who are unable to swallow capsules, or who have disease significantly affecting gastrointestinal function that would limit oral absorption of medication 4. Known serological positivity for HBV, HCV, HIV. Patients who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR) result. Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Patients who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded 5. Diagnosed with or treated for any other malignancy than MCL within 2 years prior to day 1 of cycle 1 (except basal cell carcinoma, cutaneous squamous cell carcinoma or any other in situ malignancy) 6. Active infection requiring treatment 7. Serious medical or psychiatric illness likely to interfere with participation in this clinical study 8. Concurrent treatment with another investigational agent outside of this protocol 9. Known history of drug-specific hypersensitivity or anaphylaxis to rituximab or acalabrutinib (including active product or excipient components). 10. Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand disease) 11. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura) 12. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited 13. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug 14. Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) > 2x ULN 15. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study 16. History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug 17. Breastfeeding or pregnant women 18. Concurrent participation in another therapeutic clinical trial 19. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML) 20. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study 21. Received a live virus vaccination within 28 days of first dose of study drug

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab

Locations

Country Name City State
Denmark Department of Hematology X, Odense University Hospital Odense
Denmark Department of Hematology, Zeeland University Hospital Roskilde Roskilde
Finland Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center Helsinki
Finland Oulu University Hospital Oulu
Korea, Republic of Division of Hematology-Oncology Samsung Medical Center Seoul Seoul
Norway Department of Oncology, Haukeland University Hospital Bergen
Norway Avd. for Kreftbehandling, Oslo Universitetssykehus Oslo
Norway Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus Stavanger
Norway Kreftklinikken, St Olavs Hospital Trondheim
Sweden Hematological Department, Falu Hospital, Falun Falun
Sweden Department of Hematology and Coagulation, Sahlgrenska University Hospital Göteborg
Sweden Department of Medicine, Halmstad Country Hospital Halmstad
Sweden Department of Internal Medicine, Kalmar County Hospital Kalmar
Sweden Hematologiska Kliniken, Universitetssjukhuset Linköping
Sweden Department of Medicine, Sunderbyn Hospital Luleå
Sweden Mats Jerkeman Lund
Sweden Center of Hematology, Karolinska University Hospital Stockholm
Sweden Uddevalla Hospital Uddevalla
Sweden Cancercentrum, Norrlands Universitetsjukhus Umeå
Sweden Department of Oncology, Uppsala Academic Hospital Uppsala

Sponsors (2)

Lead Sponsor Collaborator
Nordic Lymphoma Group AstraZeneca

Countries where clinical trial is conducted

Denmark,  Finland,  Korea, Republic of,  Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival The primary efficacy endpoint is progression-free survival, compared to the MCL4 data by log rank test 5 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1